{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:27:56Z","timestamp":1791581276454,"version":"4.3.4"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>STUDY QUESTION<\/jats:title>\n                  <jats:p>Is it safe to perform controlled ovarian stimulation (COS) for fertility preservation before starting anticancer therapies or ART after treatments in young breast cancer patients?<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SUMMARY ANSWER<\/jats:title>\n                  <jats:p>Performing COS before, or ART following anticancer treatment in young women with breast cancer does not seem to be associated with detrimental prognostic effect in terms of breast cancer recurrence, mortality or event-free survival (EFS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                  <jats:p>COS for oocyte\/embryo cryopreservation before starting chemotherapy is standard of care for young women with breast cancer wishing to preserve fertility. However, some oncologists remain concerned on the safety of COS, particularly in patients with hormone-sensitive tumors, even when associated with aromatase inhibitors. Moreover, limited evidence exists on the safety of ART in breast cancer survivors for achieving pregnancy after the completion of anticancer treatments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                  <jats:p>The present systematic review and meta-analysis was carried out by three blinded investigators using the keywords \u2018breast cancer\u2019 and \u2018fertility preservation\u2019; keywords were combined with Boolean operators. Eligible studies were identified by a systematic literature search of Medline, Web of Science, Embase and Cochrane library with no language or date restriction up to 30 June 2021.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                  <jats:p>To be included in this meta-analysis, eligible studies had to be case-control or cohort studies comparing survival outcomes of women who underwent COS or ART before or after breast cancer treatments compared to breast cancer patients not exposed to these strategies. Survival outcomes of interest were cancer recurrence rate, relapse rate, overall survival and number of deaths. Adjusted relative risk (RR) and hazard ratio (HR) with 95% CI were extracted. When the number of events for each group were available but the above measures were not reported, HRs were estimated using the Watkins and Bennett method. We excluded case reports or case series with &amp;lt;10 patients and studies without a control group of breast cancer patients who did not pursue COS or ART. Quality of data and risk of bias were assessed using the Newcastle-Ottawa Assessment Scale.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                  <jats:p>A total of 1835 records were retrieved. After excluding ineligible publications, 15 studies were finally included in the present meta-analysis (n = 4643). Among them, 11 reported the outcomes of breast cancer patients who underwent COS for fertility preservation before starting chemotherapy, and 4 the safety of ART following anticancer treatment completion. Compared to women who did not receive fertility preservation at diagnosis (n = 2386), those who underwent COS (n = 1594) had reduced risk of recurrence (RR 0.58, 95% CI 0.46\u20130.73) and mortality (RR 0.54, 95% CI 0.38\u20130.76). No detrimental effect of COS on EFS was observed (HR 0.76, 95% CI 0.55\u20131.06). A similar trend of better outcomes in terms of EFS was observed in women with hormone-receptor-positive disease who underwent COS (HR 0.36, 95% CI 0.20\u20130.65). A reduced risk of recurrence was also observed in patients undergoing COS before neoadjuvant chemotherapy (RR 0.22, 95% CI 0.06\u20130.80). Compared to women not exposed to ART following completion of anticancer treatments (n = 540), those exposed to ART (n = 123) showed a tendency for better outcomes in terms of recurrence ratio (RR 0.34, 95% CI 0.17\u20130.70) and EFS (HR 0.43, 95% CI 0.17\u20131.11).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                  <jats:p>This meta-analysis is based on abstracted data and most of the studies included are retrospective cohort studies. Not all studies had matching criteria between the study population and the controls, and these criteria often differed between the studies. Moreover, rate of recurrence is reported as a punctual event and it is not possible to establish when recurrences occurred and whether follow-up, which was shorter than 5 years in some of the included studies, is adequate to capture late recurrences.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                  <jats:p>Our results demonstrate that performing COS at diagnosis or ART following treatment completion does not seem to be associated with detrimental prognostic effect in young women with breast cancer, including among patients with hormone receptor-positive disease and those receiving neoadjuvant chemotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                  <jats:p>Partially supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC; grant number MFAG 2020 ID 24698) and the Italian Ministry of Health\u20145 \u00d7 1000 funds 2017 (no grant number). M.L. acted as consultant for Roche, Pfizer, Novartis, Lilly, AstraZeneca, MSD, Exact Sciences, Gilead, Seagen and received speaker honoraria from Roche, Pfizer, Novartis, Lilly, Ipsen, Takeda, Libbs, Knight, Sandoz outside the submitted work. F.S. acted as consultant for Novartis, MSD, Sun Pharma, Philogen and Pierre Fabre and received speaker honoraria from Roche, Novartis, BMS, MSD, Merck, Sun Pharma, Sanofi and Pierre Fabre outside the submitted work. I.D. has acted as a consultant for Roche, has received research grants from Roche and Ferring, has received reagents for academic clinical trial from Roche diagnostics, speaker\u2019s fees from Novartis, and support for congresses from Theramex and Ferring outside the submitted work. L.D.M. reported honoraria from Roche, Novartis, Eli Lilly, MSD, Pfizer, Ipsen, Novartis and had an advisory role for Roche, Eli Lilly, Novartis, MSD, Genomic Health, Pierre Fabre, Daiichi Sankyo, Seagen, AstraZeneca, Eisai outside the submitted work. The other authors declare no conflict of interest. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript and decision to submit the manuscript for publication.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>REGISTRATION NUMBER<\/jats:title>\n                  <jats:p>N\/A.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/humrep\/deac035","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T20:24:35Z","timestamp":1644870275000},"page":"954-968","source":"Crossref","is-referenced-by-count":106,"title":["Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-0364","authenticated-orcid":false,"given":"L","family":"Arecco","sequence":"first","affiliation":[{"name":"U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy"},{"name":"Department of Internal Medicine and Medical Sciences (DiMI), School of Medicine, University of Genova, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9566-4579","authenticated-orcid":false,"given":"E","family":"Blondeaux","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Sciences (DiMI), School of Medicine, University of Genova, Genova, Italy"},{"name":"U.O.S.D. Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8821-4542","authenticated-orcid":false,"given":"M","family":"Bruzzone","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ceppi","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8963-838X","authenticated-orcid":false,"given":"M M","family":"Latocca","sequence":"additional","affiliation":[{"name":"U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy"},{"name":"Department of Internal Medicine and Medical Sciences (DiMI), School of Medicine, University of Genova, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Marrocco","sequence":"additional","affiliation":[{"name":"U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5336-5578","authenticated-orcid":false,"given":"A","family":"Boutros","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Sciences (DiMI), School of Medicine, University of Genova, Genova, Italy"},{"name":"U.O. Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3287-1225","authenticated-orcid":false,"given":"F","family":"Spagnolo","sequence":"additional","affiliation":[{"name":"U.O. Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M G","family":"Razeti","sequence":"additional","affiliation":[{"name":"U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy"},{"name":"Department of Internal Medicine and Medical Sciences (DiMI), School of Medicine, University of Genova, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6192-2840","authenticated-orcid":false,"given":"D","family":"Favero","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Sciences (DiMI), School of Medicine, University of Genova, Genova, Italy"},{"name":"U.O.S.D. Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Spinaci","sequence":"additional","affiliation":[{"name":"Breast Unit, Ospedale Villa Scassi, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1104-8208","authenticated-orcid":false,"given":"M","family":"Condorelli","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles (U.L.B), Brussels, Belgium"},{"name":"Research Laboratory on Human Reproduction, Universit\u00e9 Libre de Bruxelles (U.L.B), Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1905-2786","authenticated-orcid":false,"given":"C","family":"Massarotti","sequence":"additional","affiliation":[{"name":"Physiopathology of Human Reproduction Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy"},{"name":"Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOGMI), School of Medicine, University of Genova, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7794-3133","authenticated-orcid":false,"given":"O","family":"Goldrat","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles (U.L.B), Brussels, Belgium"},{"name":"Research Laboratory on Human Reproduction, Universit\u00e9 Libre de Bruxelles (U.L.B), Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9546-5841","authenticated-orcid":false,"given":"L","family":"Del Mastro","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Sciences (DiMI), School of Medicine, University of Genova, Genova, Italy"},{"name":"U.O.S.D. Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3192-6565","authenticated-orcid":false,"given":"I","family":"Demeestere","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles (U.L.B), Brussels, Belgium"},{"name":"Research Laboratory on Human Reproduction, Universit\u00e9 Libre de Bruxelles (U.L.B), Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-5296","authenticated-orcid":false,"given":"M","family":"Lambertini","sequence":"additional","affiliation":[{"name":"U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy"},{"name":"Department of Internal Medicine and Medical Sciences (DiMI), School of Medicine, University of Genova, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,27]]},"reference":[{"key":"2022050519303065300_deac035-B1","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1200\/JCO.2007.14.8700","article-title":"Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study","volume":"26","author":"Azim","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022050519303065300_deac035-B2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s13058-014-0427-5","article-title":"Biology of breast cancer in young women","volume":"16","author":"Azim","year":"2014","journal-title":"Breast Cancer Res"},{"key":"2022050519303065300_deac035-B3","first-page":"753","article-title":"High yield of oocytes without an increase in circulating estradiol levels in breast cancer patients treated with follicle-stimulating hormone and aromatase inhibitor in standard gonadotropin-releasing hormone analogue protocols","volume":"13","author":"Ben-Haroush","year":"2011","journal-title":"Isr Med Assoc J"},{"key":"2022050519303065300_deac035-B4","doi-asserted-by":"crossref","first-page":"690320","DOI":"10.3389\/fonc.2021.690320","article-title":"The PREgnancy and FERtility (PREFER) Study Investigating the need for ovarian function and\/or fertility preservation strategies in premenopausal women with early breast cancer","volume":"11","author":"Blondeaux","year":"2021","journal-title":"Front Oncol"},{"key":"2022050519303065300_deac035-B5","doi-asserted-by":"crossref","first-page":"574669","DOI":"10.3389\/fonc.2020.574669","article-title":"Efficacy and safety of controlled ovarian stimulation with or without letrozole co-administration for fertility preservation: a systematic review and meta-analysis","volume":"10","author":"Bonardi","year":"2020","journal-title":"Front Oncol"},{"key":"2022050519303065300_deac035-B6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10549-017-4288-3","article-title":"Fertility preservation with ovarian stimulation and time to treatment in women with stage II\u2013III breast cancer receiving neoadjuvant therapy","volume":"165","author":"Chien","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"2022050519303065300_deac035-B7","doi-asserted-by":"crossref","first-page":"100300","DOI":"10.1016\/j.esmoop.2021.100300","article-title":"Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1\/2 with a pregnancy after prior history of breast cancer","volume":"6","author":"Condorelli","year":"2021","journal-title":"ESMO Open"},{"key":"2022050519303065300_deac035-B8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/humrep\/deaa319","article-title":"Impact of ARTs on oncological outcomes in young breast cancer survivors","volume":"36","author":"Condorelli","year":"2021","journal-title":"Hum Reprod"},{"key":"2022050519303065300_deac035-B9","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2013.49.7693","article-title":"Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer","volume":"32","author":"de Melo Gagliato","year":"2014","journal-title":"J Clin Oncol"},{"key":"2022050519303065300_deac035-B10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1634\/theoncologist.2019-0744","article-title":"Impact of delayed neoadjuvant systemic chemotherapy on overall survival among patients with breast cancer","volume":"25","author":"de Melo Gagliato","year":"2020","journal-title":"Oncologist"},{"key":"2022050519303065300_deac035-B11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"2022050519303065300_deac035-B12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"2022050519303065300_deac035-B13","doi-asserted-by":"crossref","first-page":"hoaa061","DOI":"10.1093\/hropen\/hoaa061","article-title":"Gonadotrophin stimulation and risk of relapse in breast cancer","volume":"2021","author":"Fredriksson","year":"2021","journal-title":"Hum Reprod Open"},{"key":"2022050519303065300_deac035-B14","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.ejca.2015.05.007","article-title":"Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome","volume":"51","author":"Goldrat","year":"2015","journal-title":"Eur J Cancer"},{"key":"2022050519303065300_deac035-B15","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1002\/cncr.33601","article-title":"The impact of fertility preservation on the timing of breast cancer treatment, recurrence, and survival","volume":"127","author":"Greer","year":"2021","journal-title":"Cancer"},{"key":"2022050519303065300_deac035-B16","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/GO.22.00008","article-title":"Is fertility preservation feasible and safe with neoadjuvant therapy for breast cancer?","author":"Hershlag","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"2022050519303065300_deac035-B17","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"2022050519303065300_deac035-B18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"2022050519303065300_deac035-B19","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1210\/jc.2015-3878","article-title":"Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer","volume":"101","author":"Kim","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2022050519303065300_deac035-B20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.breast.2018.08.099","article-title":"The BCY3\/BCC 2017 survey on physicians\u2019 knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients","volume":"42","author":"Lambertini","year":"2018","journal-title":"Breast"},{"key":"2022050519303065300_deac035-B21","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.rbmo.2018.11.031","article-title":"Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients","volume":"38","author":"Lambertini","year":"2019","journal-title":"Reprod Biomed Online"},{"key":"2022050519303065300_deac035-B22","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.annonc.2020.09.006","article-title":"Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines","volume":"31","author":"Lambertini","year":"2020","journal-title":"Ann Oncol"},{"key":"2022050519303065300_deac035-B23","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/cncr.32546","article-title":"Fertility preservation before breast cancer treatment appears unlikely to affect disease-free survival at a median follow-up of 43 months after fertility-preservation consultation","volume":"126","author":"Letourneau","year":"2020","journal-title":"Cancer"},{"key":"2022050519303065300_deac035-B24","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1200\/JCO.2005.01.6089","article-title":"Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer","volume":"24","author":"Lohrisch","year":"2006","journal-title":"J Clin Oncol"},{"key":"2022050519303065300_deac035-B25","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/humrep\/deaa029","article-title":"Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer\u2014a prospective nationwide Swedish multicenter study","volume":"35","author":"Marklund","year":"2020","journal-title":"Hum Reprod"},{"key":"2022050519303065300_deac035-B26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1001\/jamaoncol.2020.5957","article-title":"Reproductive outcomes after breast cancer in women with vs without fertility preservation","volume":"7","author":"Marklund","year":"2021","journal-title":"JAMA Oncol"},{"key":"2022050519303065300_deac035-B27","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.fertnstert.2014.05.017","article-title":"Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies","volume":"102","author":"Meirow","year":"2014","journal-title":"Fertil Steril"},{"key":"2022050519303065300_deac035-B28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21637","article-title":"Cancer statistics for adolescents and young adults, 2020","volume":"70","author":"Miller","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"2022050519303065300_deac035-B29","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"2022050519303065300_deac035-B30","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-020-06031-4","article-title":"Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation","volume":"186","author":"Moravek","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"2022050519303065300_deac035-B31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.fertnstert.2017.10.029","article-title":"Long-term outcomes in cancer patients who did or did not pursue fertility preservation","volume":"109","author":"Moravek","year":"2018","journal-title":"Fertil Steril"},{"key":"2022050519303065300_deac035-B32","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.rbmo.2019.07.003","article-title":"Ovarian stimulation for oocyte vitrification does not modify disease-free survival and overall survival rates in patients with early breast cancer","volume":"39","author":"Mu\u00f1oz","year":"2019","journal-title":"Reprod Biomed Online"},{"key":"2022050519303065300_deac035-B33","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1200\/JCO.2005.05.037","article-title":"Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation","volume":"23","author":"Oktay","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022050519303065300_deac035-B34","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","article-title":"Fertility preservation in patients with cancer: ASCO clinical practice guideline update","volume":"36","author":"Oktay","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022050519303065300_deac035-B35","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"key":"2022050519303065300_deac035-B36","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1200\/JCO.2015.65.8013","article-title":"Subtype-dependent relationship between young age at diagnosis and breast cancer survival","volume":"34","author":"Partridge","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022050519303065300_deac035-B37","doi-asserted-by":"crossref","first-page":"e000771","DOI":"10.1136\/esmoopen-2020-000771","article-title":"specific aspects related to type of fertility preservation strategies and access to fertility care","volume":"5","author":"Perachino","year":"2020","journal-title":"ESMO Open"},{"key":"2022050519303065300_deac035-B38","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s10549-017-4555-3","article-title":"Safety of fertility preservation in breast cancer patients in a register-based matched cohort study","volume":"167","author":"Rodriguez-Wallberg","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"2022050519303065300_deac035-B39","doi-asserted-by":"crossref","first-page":"hoz039","DOI":"10.1093\/hropen\/hoz039","article-title":"No increased risk of relapse of breast cancer for women who give birth after assisted conception","volume":"2019","author":"Rosenberg","year":"2019","journal-title":"Hum Reprod Open"},{"key":"2022050519303065300_deac035-B40","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/tbj.13083","article-title":"Assisted reproductive technology is effective for but does not affect the prognosis of young patients with breast cancer: experience in a single institution","volume":"24","author":"Takuwa","year":"2018","journal-title":"Breast J"},{"key":"2022050519303065300_deac035-B41","doi-asserted-by":"crossref","first-page":"hoaa052","DOI":"10.1093\/hropen\/hoaa052","article-title":"ESHRE guideline: female fertility preservation","volume":"2020","author":"The ESHRE Guideline Group on Female Fertility Preservation","year":"2020","journal-title":"Hum Reprod Open"},{"key":"2022050519303065300_deac035-B42","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.fertnstert.2013.08.030","article-title":"Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients","volume":"100","author":"Turan","year":"2013","journal-title":"Fertil Steril"},{"key":"2022050519303065300_deac035-B43","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10549-020-05598-2","article-title":"Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastricht experience","volume":"181","author":"Vriens","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"2022050519303065300_deac035-B44","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/jrsm.1301","article-title":"A simple method for combining binomial counts or proportions with hazard ratios for evidence synthesis of time-to-event data","volume":"9","author":"Watkins","year":"2018","journal-title":"Res Synth Methods"},{"key":"2022050519303065300_deac035-B45","author":"Wells"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/advance-article-pdf\/doi\/10.1093\/humrep\/deac035\/42622687\/deac035.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/37\/5\/954\/43541464\/deac035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/37\/5\/954\/43541464\/deac035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T20:24:32Z","timestamp":1651782272000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/37\/5\/954\/6537993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,27]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,2,27]]},"published-print":{"date-parts":[[2022,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deac035","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2022,2,27]]}}}